Literature DB >> 28574205

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties.

P Collins1, E Chalmers2, J Alamelu3, C Hay4, R Liesner5, M Makris6, M Mathias5, J Payne7, S Rangarajan8, M Richards9, K Talks10, O Tunstall11, M Williams12, D P Hart13.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28574205     DOI： 10.1111/hae.13264

Source DB:  PubMed          Journal:  Haemophilia        ISSN： 1351-8216            Impact factor:   4.287


× No keyword cloud information.
  8 in total

Review 1.  Advances and innovations in haemophilia treatment.

Authors:  Rob Peters; Tim Harris
Journal:  Nat Rev Drug Discov       Date:  2018-06-08       Impact factor: 84.694

2.  Immune Tolerance Induction (ITI) with a pdFVIII/VWF Concentrate (octanate) in 100 Patients in the Observational ITI (ObsITI) Study.

Authors:  Carmen Escuriola Ettingshausen; Vladimír Vdovin; Nadezhda Zozulya; Pavel Svirin; Tatiana Andreeva; Majda Benedik-Dolničar; Victor Jiménez-Yuste; Lidija Kitanovski; Silva Zupancic-Šalek; Anna Pavlova; Angelika Bátorová; Cesar Montaño Mejía; Gulnara Abdilova; Sigurd Knaub; Martina Jansen; Shannely Lowndes; Larisa Belyanskaya; Olaf Walter; Johannes Oldenburg
Journal:  TH Open       Date:  2022-05-26

3.  Expert opinion on the UK standard of care for haemophilia patients with inhibitors: a modified Delphi consensus study.

Authors:  Kate Khair; Elizabeth Chalmers; Thuvia Flannery; Annabel Griffiths; Felicity Rowley; Guillermo Tobaruela; Pratima Chowdary
Journal:  Ther Adv Hematol       Date:  2021-04-30

4.  The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab.

Authors:  Manuel Carcao; Carmen Escuriola-Ettingshausen; Elena Santagostino; Johannes Oldenburg; Ri Liesner; Beatrice Nolan; Angelika Bátorová; Saturnino Haya; Guy Young
Journal:  Haemophilia       Date:  2019-04-29       Impact factor: 4.287

5.  [Chinese guidelines on the diagnosis and treatment of coagulation factor Ⅷ/Ⅸ inhibitors (version 2018)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-10-14

6.  Low-dose immune tolerance induction for children with hemophilia A with poor-risk high-titer inhibitors: A pilot study in China.

Authors:  Zekun Li; Zhenping Chen; Xiaoling Cheng; Xinyi Wu; Gang Li; Yingzi Zhen; Siyu Cai; Man-Chiu Poon; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2019-08-09

7.  Low-dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors.

Authors:  Zekun Li; Zhenping Chen; Guoqing Liu; Xiaoling Cheng; Wanru Yao; Kun Huang; Gang Li; Yingzi Zhen; Xinyi Wu; Siyu Cai; Man-Chiu Poon; Runhui Wu
Journal:  Res Pract Thromb Haemost       Date:  2021-07-14

Review 8.  Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Authors:  Alfonso Iorio; Andrea N Edginton; Victor Blanchette; Jan Blatny; Ana Boban; Marjon Cnossen; Peter Collins; Stacy E Croteau; Katheljin Fischer; Daniel P Hart; Shinya Ito; Joan Korth-Bradley; Stefan Lethagen; David Lillicrap; Mike Makris; Ron Mathôt; Massimo Morfini; Ellis J Neufeld; Jeffrey Spears
Journal:  Res Pract Thromb Haemost       Date:  2018-05-20
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.